



## Non-interventional study (NIS) information

<b>Title / acronym</b>	Encorafenib and cetuximab in patients with metastatic, BRAF <sup>V600E</sup> -mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria / <b>BRAF inhibitor Encorafenib and Cetuximab Real life Investigation of Next Generation CRC treatment / BERING<sup>CRC</sup></b>	
<b>Version identifier</b>	Final 2.0	
<b>Date of current version</b>	08 July 2022	
<b>Active substances</b>	Encorafenib: ATC-code L01XE46 Cetuximab: ATC-code L01XC06	
<b>Medicinal products</b>	Encorafenib: Braftovi® 50/75 mg hard capsules Cetuximab: Erbitux® 5mg/ml solution for infusion (or Cetuximab-biosimilar, if available and used)	
<b>Product references</b>	Encorafenib marketing authorization nos.: EU/1/18/1314/001 EU/1/18/1314/003 EU/1/18/1314/002 EU/1/18/1314/004 Cetuximab marketing authorization nos.: EU/1/04/281/003 EU/1/04/281/005	
<b>Marketing authorization holders</b>	<u>Encorafenib</u> : Pierre Fabre Médicament; Boulogne-Billancourt, France <u>Cetuximab</u> : Merck KGaA; Darmstadt, Germany	
<b>Research question and main objectives</b>	Data from a pivotal clinical trial are usually based on a selected patient population in order to provide standardized results in the given indication. However, after marketing authorization usage in a broader patient population is to be expected. European approval of the doublet therapy encorafenib and cetuximab for patients with pretreated metastatic colorectal cancer (mCRC) harboring a BRAF <sup>V600E</sup> mutation is applied for based on the pivotal clinical trial BEACON CRC: When compared to standard chemotherapy the doublet therapy showed favorable efficacy results in terms of overall response rate (ORR) and overall survival (OS). BERING <sup>CRC</sup> NIS – designed as a prospective, longitudinal, non-interventional study – will investigate the real-world effectiveness, quality of life, safety and tolerability of encorafenib and cetuximab in a broad patient population with mCRC harboring a BRAF <sup>V600E</sup> mutation, who have received prior systemic therapy.	
<b>Countries</b>	Germany (ca. 70-80 centers) & Austria (ca. 10-20 centers)	
<b>Authors</b>	 iOMEDICO AG Ellen-Gottlieb-Straße 19 79106 Freiburg, Germany Phone: +49 (0)761 15242-0 Email: info@iomedico.com	 Pierre Fabre Pharma GmbH Neuer Messplatz 5, 79108 Freiburg, Germany Phone: +49 (0)761 45261-0 Email: beringcrc_de@pierre-fabre.com beringcrc_at@pierre-fabre.com